ReviewCommunications medicine2026
Functional antibody responses and protection against symptomatic dengue.
Review in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exposure to dengue virus (DENV) triggers the development of anti-viral antibodies that may contribute to either protection or disease progression. Antibodies exist in different isotypes and subtypes, with diverse specificities and functions. IgG antibodies are produced during primary and secondary DENV infections, where they play a role central role in mediating protective immunity, and may also contribute to antibody-dependent enhancement in a secondary heterotypic infection. Although IgG antibodies are widely recognised as key mediators of protective immune responses during DENV infection, antibody specificities, types and functions that reliably correlate with protection remain unclear. A better understanding of anti-DENV antibodies and their roles in protection against symptomatic dengue is essential especially in guiding the design of dengue vaccines. In this review, antibody functions and effector mechanisms in DENV infection are discussed, with a focus on naturally acquired immunity and neutralising antibody responses following vaccination. In addition, current knowledge gaps in antibody functions during DENV infection will be highlighted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.